Home What’s New

31

Jan2024

CADTH Update Introduces Streamlined Economic Reports and Launches BIA Template Consultation

On Friday, CADTH’s Pharmaceutical Reviews Update – Issue 43 introduced a number of updates pertaining to its Reimbursement Reviews procedures. These include: Budget Impact Analysis (BIA) Consultation: CADTH is seeking stakeholder feedback on its draft BIA template tool. The tool is an optional resource to ... Read More

20

Dec2023

New Issue of INSIGHTS Released

PDCI released a new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. In this Issue:... Read More

19

Dec2023

Happy Holidays from PDCI!

As another memorable year draws to a close, the team at PDCI Market Access would like to express its sincere gratitude and appreciation for all our clients, partners, and people who support us in our purpose to improve health outcomes for all.We hope your holiday season is filled ... Read More

02

Oct2023

PMPRB Publishes Final Decision on Amended Interim Guidance

On September 27, 2023, the Patented Medicine Prices Review Board (PMPRB) published its final decision regarding the Amended Interim Guidance first proposed on June 20, 2023.Effective immediately, the proposed amendments to the Interim Guidance are implemented without changes, notwithstanding the concerns raised by many of the ... Read More

03

Aug2023

PCPA Seeks Stakeholder Input On Its Proposed Process To Implement CADTH Time-Limited Recommendations

The pan-Canadian Pharmaceutical Alliance (pCPA) introduced its proposed pCPA Temporary Access Process (pTAP) and invited stakeholders’ input on the process, its principles and conditions by August 18th, 2023.   The proposed pTAP and its associated principles are intended to inform pCPA negotiations and product listing agreements for ... Read More

11

Jul2023

CADTH Announces Changes to Reimbursement Reviews Process & Fee Schedule Update

On June 5, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced a series of process improvements it plans to explore or add to its drug reimbursement review process. These changes - aimed at gaining efficiencies, reducing timelines and improving transparency – include:... Read More

22

Nov2022

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More

22

Nov2022

PDCI Well Wishes for Managing Director Kaitlyn Proulx

PDCI is congratulating its Managing Director, Kaitlyn Proulx, as she begins parental leave effective November 28, 2022.Since joining PDCI in 2010, Kaitlyn has demonstrated incredible strategic insights advising clients on optimizing pricing and market access in Canada. Since becoming Managing Director in 2017, Kaitlyn has ... Read More

06

Oct2022

PMPRB Releases Draft Guidelines and Launches 60-day consultation 

The Patented Medicine Prices Review Board (PMPRB) today, Ocober 6, 2022, released its draft PMPRB Guidelines with a 60-day consultation period running until December 5, 2022. PMPRB maintains that final Guidelines will be issued by end of this year and previously indicated its intent for new Guidelines ... Read More

19

Aug2022

PMPRB Implements its Interim Guidelines with Clarifications

On August 18, 2022, PMPRB announced its decisions regarding Price Regulation of patented medicines during the ‘Interim Period’, between July 1, 2022 and when a final set of price regulatory guidelines is published. The PMPRB has decided to move forward with earlier proposals drafted June 30th, 2022, and ... Read More